Lupin Purchases Instem Preclinical Software for Novel Drug Discovery & Development Program
Provantis Preclinical Software Selected to Automate Study Processes at Lupin's Global R&D Hub in Pune, India
CONSHOHOCKEN, PA - (BUSINESS WIRE) - May 1, 2012 - - Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that Lupin Limited (Lupin) has purchased the Provantis® preclinical software solution. Provantis will be deployed at the Lupin Research Park, the company’s state-of-the art global R&D hub in Pune, India, housing over 1,000 scientists.
Lupin is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and active pharmaceutical ingredients (APIs) for the developed and developing markets of the world. Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).
- Integrated Inlife Toxicology and Pathology modules purchased as well as a number of Clinical Pathology interfaces
- A range of Professional Services contracted including validation and training to ensure quicker, smoother implementation
- Instem’s Data Import module purchased for rapid entry of Clinical Pathology data
- Competitive evaluation undertaken; Provantis selected for product functionality and technology
Dr. Rajender Kamboj, President, Novel Drug Discovery & Development, Lupin comments “We were looking for a world-class solution to support the automation of our laboratory processes, further improve productivity and ensure GLP compliance for Lupin’s core Novel Drug Discovery & Development research programs. Following a thorough competitive review, we are satisfied that Provantis is the right solution to help us meet these needs.”
Demand for regulatory toxicology services has grown within India in recent years, fueled by the internal investments of Indian pharmaceutical and chemical companies, the recent addition of India within the OECD Mutual Acceptance of Data program and the demand from elsewhere in the world for high-quality, cost-effective non-clinical services.
Instem’s VP of Asian and European Operations, Neil Donaldson adds “We are delighted to welcome Lupin to our growing roster of clients in the Asia Pacific region. Instem recognizes the important role that Indian organizations play in this increasingly competitive global market and given our presence in the region and our commitment to the Indian R&D community, we are ideally placed to support their future growth.”
Instem entered the early drug development market in India in 2005 with its first customer, Advinus Therapeutics. Instem has maintained a physical resource location in India for several years and further cemented its commitment to the market in March with the establishment of Instem India, a wholly owned subsidiary of the company based in Pune.
About Lupin Limited
Headquartered in Mumbai, India, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).
For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 Million (USD 1.28 Billion) and Rs. 8,626 Million (USD 193 Million) respectively.
Please visit www.lupinworld.com for more information on Lupin Ltd.
Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.
Meeting clients at the intersection of investment & return™.
Gary Mitchell (US HQ)
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600